 AGOURA HILLS, Calif., Dec. 30, 2020 GLOBE NEWSWIRE -- Mateon Therapeutics, Inc. Mateon or the Company OTCQB:MATN announced today that it has enrolled and treated its first sentinel Part 1 patient with COVID-19. 